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Dear Editor,
TRAIL induces apoptotic cell death upon binding to either of
two proapoptotic TRAIL receptors, TRAIL R1 (DR4)1 or TRAIL
R2 (KILLER/DR5).2 Activation of the proapoptotic death
receptors by TRAIL engagement induces the formation of a
death-inducing signaling complex (DISC), which consists of
receptor, FADD, as an adaptor,3 and caspase 8 as an initiator
caspase. Once the DISC is formed, the caspase 8 is
autoprocessed and activated by induced proximity.4 In FAS/
FASL-mediated apoptosis, two types of apoptotic signaling
pathways5 exist, namely type I and type II. In type I cells, the
activated caspase 8 could directly activate executioner
caspase 3 without the involvement of the mitochondrial
pathway. Even though either Bcl-2 or Bcl-xL may be over-
expressed, the apoptotic signaling is not blocked in type I
cells. In type II cells, there is little caspase 8 recruitment into
the DISC; not enough to efficiently activate caspase 3, but
enough to activate the mitochondrial pathway. Bid plays an
important role in bridging signals from death receptors
(extrinsic pathway) to the mitochondria (intrinsic pathway).
Activated caspase 8 cleaves Bid and then, truncated Bid (tBid)
translocates into mitochondria followed by Bax translocation,
BAK oligomerization, cytochrome c release, and activation of
caspase 9 and the other downstream caspases.6,7 The
overexpression of either Bcl-2 or Bcl-xL could completely
block the apoptotic signaling in type II cells. The observations
that Bid is cleaved in TRAIL-mediated apoptosis,8 that some
Bcl-2- or Bcl-xL-overexpressing cells are still sensitive to
TRAIL,9 and that in the presence of z-LEHD-FMK, a caspase
9 inhibitor, caspase 3 is activated in some cancer cells but not
in other cancer cells10 suggest that the same types of
pathways (type I and type II) may be utilized in TRAIL-
mediated apoptosis. TRAIL is a promising agent for develop-
ment as a cancer therapeutic because it appears to
specifically kill transformed and cancer cells, whereas most
normal cells appear to be resistant to TRAIL.11 Systemic
administration of TRAIL is safe in mice and can kill breast or
colon-xenografted tumors and prolong survival.11 However,
the potential utility and safety of systemic administration of
TRAIL has been questioned recently because of results
showing sensitivity of human but not monkey or mouse
hepatocytes to recombinant human TRAIL in vitro.12 Re-
cently, we proposed the use of a specific caspase 9 inhibitor to
circumvent that side effect based on the fact that hepatocytes
are type II cells, and the inhibitor could rescue TRAIL
hepatocytotoxicity without affecting the TRAIL killing effect
towards cancer cells, many of which use a type I pathway in
apoptotic signaling.10 Although TRAIL could specifically kill
cancer cells, there are still many cancer cells that are TRAIL
resistant.13 A number of mechanisms of TRAIL resistance
have been described. For example, low or undetectable
expression of DR413 or overexpression of TRAIL-decoy
receptors, such as TRID (DcR1 or TRAIL-R3)14 or TRUNDD
(DcR2, or TRAIL-R4),15 could block TRAIL-mediated apopto-
tic signaling. Loss of caspase 8 expression16 or high
expression of c-FLIP13,17 make cancer cells also resistant to
TRAIL. At the mitochondrial level, high expression of
antiapoptotic Bcl-2 family proteins such as Bcl-2 or Bcl-xL
might block death signal propagation if the cells use a type II
pathway.5 Loss of expression of Apaf-1 documented in
malignant melanoma could also provide a possible mechan-
ism for TRAIL resistance at a postmitochondrial level.18 It was
additionally reported that elevated AKT activity conferred
TRAIL resistance on LnCap, a prostate cancer cell line, in a
tissue-specific manner.19
Little is known about the effects of TRAIL on the human
gastrointestinal epithelium. To gain a better understanding of
TRAIL-mediated apoptosis, we chose for the present study
human esophageal tissue, including eight squamous esopha-
geal cancer cell lines and one normal primary esophageal
epithelial cell. To assess TRAIL cytotoxicity towards squa-
mous esophageal cancer cells, we performed the active-
caspase 3 assay. With this assay, when more than 15% of
cells revealed active-caspase 3 in a cell line, we defined the
cell line as TRAIL sensitive. With this definition, three
esophageal cancer cell lines (TE2, TE9, and TE12) were
sensitive to TRAIL (Figure 1a). Cycloheximide reversed the
TRAIL resistance in all cases. Previously, we reported that the
expression levels of DR4 or c-FLIP were well correlated with
TRAIL sensitivity.13 To evaluate determinants for TRAIL
sensitivity in esophageal cancer cell lines, we performed
Western blot immunostaining for expression of proteins
involved in mediating the death signal (Figure 1b). Proapop-
totic death receptors were highly expressed in TRAIL-
resistant cancer cells and antiapoptotic decoy receptors were
Cell Death and Differentiation (2004) 11, 583–587
& 2004 Nature Publishing Group All rights reserved 1350-9047/04 $25.00
www.nature.com/cdd
expressed in every cancer cell line. Furthermore, TRID
expression in EPC2 was lower than in the cancer cell lines.
The expression level of FADD did not correlate with TRAIL
sensitivity and c-FLIP, the inhibitor of caspase 8 activation,
also showed no correlation with TRAIL sensitivity being
undetectable on Western blot immunostaining in TRAIL-
Figure 1 Analysis of determinants of TRAIL mediated cytotoxicity suggests sensitivity of primary esophageal epithelial cells as well as esophageal tumors, while there
is some correlation between TRAIL resistance and overexpression of Bcl-xL in TRAIL-resistant esophageal squamous cell carcinomas. (a) TRAIL cytotoxicity toward
squamous esophageal cancer cells in the presence or absence of CHX. Each cancer cell line (5 105 cells/well) was seeded onto a six-well plate and the cells were
treated with TRAIL crosslinked with anti-6X His Ab. After 16 h of TRAIL treatment, cells were harvested and an active-caspase 3 assay was performed. In case of CHX
treatment, the cells were pretreated with CHX (10 mg/ml final concentration) for 6 h before the addition of TRAIL. We defined the cells as TRAIL sensitive when more than
30% of the cell population activated caspase 3. Experiments were performed in duplicate (mean value7S.D.). Human esophageal cancer cell lines were previously
described. All the esophageal cancer cell lines were grown with DMEM containing 10% FCS. Primary normal esophageal epithelial cells (EPC2) were established from
normal human esophagus (unpublished data, Yasir Suliman, Oliver G Opitz and Anil K Rustgi). EPC2 cells have a diploid karyotype, and express E-cadherin as well as
cytokeratins K4, K5, K13, and K14. EPC2 cells were grown in Keratinocyte-SFM medium (Gibco BRL, Rockville, MD, USA) containing bovine pituitary extract (40 mg/ml)
and epidermal growth factor (1 ng/ml). For detecting apoptosis mediated by TRAIL, an active-caspase 3 assay was performed using the Cytofix/Cytoperm kit
(Pharmingen, San Diego, CA, USA) as previously described. Briefly, 5 105 cells were seeded onto a six-well plate, after which, the cells were treated with TRAIL
crosslinked with anti-6X His Ab. After 4 or 16 h of treatment, the cells were harvested, fixed, and then incubated with 0.125 mg/ml rabbit anti-active-caspase 3 Ab (Clone
C92-605; Pharmingen) for 20 min in a dark room. After washing, the cells were probed with 0.125 mg/ml of the phycoerythrin (PE)-conjugated goat anti-rabbit secondary
Ab (CALTAG Laboratories, Burlingame, CA, USA) for 20 min in a dark room. The intensity of PE was analyzed by flow cytometry using a Beckman–Coulter Epics Elite
analyzer. The N-terminal histidine (His)-tagged recombinant human TRAIL (rhTRAIL, Thr-95 to Gly-281) was obtained from R&D Systems (Minneapolis, MN, USA). A
mouse monoclonal anti-6X His antibody (R&D Systems) was used for crosslinking of the rhTRAIL. Cells were treated with 50 ng/ml final concentration of TRAIL and 1mg/
ml of anti-6X His Ab for 4 or 16 h. When the cells were treated with both cycloheximide (CHX) and TRAIL, CHX (10 mg/ml final concentration) was added 6 h before the
addition of TRAIL. In the case of adriamycin, cells were pretreated with adriamycin (0.5 mM final concentration) for 16 h before the addition of TRAIL. (b) Relative
expression level of signaling molecules involved in TRAIL-mediated apoptosis. Cell lysates were subjected to 12 or 15% SDS-PAGE, and then immunostained with Abs
are indicated in the figure. TRAIL sensitivity was defined by the results of active-caspase 3 assay (see Figure 1); S¼ sensitive, R¼ resistant. Western blot analysis was
carried out as previously described. Blotted membranes were immunostained with anti-DR4 (1 : 500; Pharmingen), anti-DR5 (1 : 500; IMGENEX, San Diego, CA, USA),
anti-DcR1 (1 : 500; Pharmingen), anti-DcR2 (1 : 500; Pharmingen), anti-FADD (Clone IF7, 1 : 2000; Upstate Biotechnology, Lake Placid, NY, USA), anti-caspase 8
(Clone 5F7, 1 : 1000; Upstate Biotechnology), anti-FLIP (Clone Dave-2, 1 : 1000; Alexis Biochemicals, San Diego, CA, USA), anti-Bid (1 : 500; Pharmingen), anti-Bax
(1 : 500, Pharmingen), anti Bcl-2 (Bcl-2/100, 1 : 500; Pharmingen), anti-Bcl-xL (1 : 500; Pharmingen), anti-caspase 3 (E-8, 1 : 200; Santa Cruz, Santa Cruz, CA, USA),
anti-PARP (1 : 2000; Roche Diagnostics GmbH, Mannheim, Germany), anti-TRAIL (1 : 500; PeproTech Inc., Rocky Hill, NJ, USA), or anti-actin (I-19, 1 : 200; Santa
Cruz). (c) Bcl-xL is overexpressed in human esophageal squamous cell carcinoma specimens. Bcl-xL staining in normal human esophagus and three archival
esophageal squamous cell carcinoma specimens. For the cancer (CA) case labeled #17, the normal esophageal tissue was obtained from the same patient. We used as
primary antibody the mouse anti-human Bcl-xL monoclonal antibody (Clone 2H12) obtained from Zymed (San Francisco, CA, USA) at a dilution of 1 : 50 in an overnight
incubation at 41C. (d) Active-caspase 3 assay for apoptosis after treatment with either TRAIL alone or TRAIL plus adriamycin (0.5 mM) in the presence or absence of z-
LEHD-FMK on EPC2 normal esophageal epithelial cells. EPC2 (5 105) cells were treated with TRAIL (50 ng/ml) for 4 h. (e) Preferential cytoprotective effect of z-
LEHD-FMK from TRAIL-mediated apoptosis in esophageal cells. Both EPC2-GFP (2 105 cells) and TRAIL-sensitive TE2 (5 105 cells) were grown in a six-well plate,
and the cells were treated with TRAIL for 4 h in the presence or absence of z-LEHD-FMK. The active-caspase 3 assay was performed and the two populations of cells
(EPC2-GFP and TE2) were discriminated by the presence or absence of green fluorescence. A bar graph is shown on the right to display the same result quantitatively.
Experiments were performed in duplicate (mean value7S.D.). The irreversible caspase inhibitors z-LEHD-FMK (caspase 9 inhibitor), z-IETD-FMK (caspase 8 inhibitor),
and z-VAD-FMK (Pan caspase inhibitor) were obtained from R&D Systems. The caspase inhibitor was used at a final concentration of 20 mM and was added 2 h prior to
the addition of TRAIL
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resistant HCE4 and HCE7. c-FLIP was highly expressed in
the TRAIL-sensitive TE2 and TE9 esophageal cancer cell
lines. Procaspase 8 was expressed in all cell lines tested, and
thus it does not appear to be silenced for example through
hypermethylation. Bid was equivalently expressed and there
was no difference among the cancer cell lines that could be
correlated with TRAIL sensitivity or resistance. Antiapoptotic
Bcl-2 or Bcl-xL were variable in expression and TRAIL-
sensitive TE2 and TE9 showed high-level expression of Bcl-2.
However, the TRAIL-resistant cell lines TE3 and TE5
expressed high levels of Bcl-xL. Proapoptotic Bax appeared
constantly expressed among the cell lines. Taken together, in
squamous esophageal cancers, the expression level of the
molecules known to be involved in TRAIL-mediated apoptosis
did not correlate universally with TRAIL sensitivity, although
some TRAIL-resistant cell lines appeared to express high
levels of Bcl-xL. We found that Bcl-xL was highly expressed in
several archival esophageal squamous cell carcinomas
tested (Figure 1c).
The fact that TRAIL has cytotoxicity toward normal human
hepatocytes could hamper its use as a cancer therapeutic in
humans. Recently, however, we reported that z-LEHD-FMK
could rescue the normal human hepatocytes from TRAIL-
mediated apoptosis.10 Accordingly, we tested EPC2 for
TRAIL sensitivity and EPC2 showed cytotoxicity in a dose-
dependent manner (data not shown). When compared to the
human foreskin keratinocyte (HFK), even at lower concentra-
tions of TRAIL (5, 10, 25, or 50 ng/ml), EPC2 cells were
sensitive to TRAIL while HFK were not affected (data not
shown). We then tested the effect of the caspase 9 inhibitor z-
LEHD-FMK on EPC2, and z-LEHD-FMK could completely
protect the cells from TRAIL-mediated apoptosis even in the
presence of adriamycin (Figure 1d). We also tested whether z-
LEHD-FMK could protect TRAIL-sensitive esophageal cancer
cells from apoptosis. We found that even in the presence of z-
LEHD-FMK, TRAIL-sensitive esophageal cancer cells under-
went apoptosis although the extent of apoptosis was slightly
reduced (data not shown). We further confirmed this
observation by incubating TRAIL in the presence or absence
of z-LEHD-FMK with a mixed culture of EPC2-GFP and
TRAIL-sensitive TE2. Active-caspase 3 assay results showed
that EPC2-GFP cells (Figure 1e, C9I/TR) were almost
completely protected from TRAIL-mediated apoptosis in the
presence of z-LEHD-FMK, but TE2 (Figure 1e, C9I/TR) were
still undergoing apoptosis. These results indicate that the
combination of the caspase 9 inhibitor and TRAIL could be a
useful strategy to circumvent undesirable cytotoxicity of
TRAIL toward normal human cells or tissues as previously
reported with normal human hepatocytes.10
Previously, we reported that the combination of adriamycin
and TRAIL could induce apoptosis synergistically in TRAIL-
resistant cancer cell lines irrespective of p53 status.13
Accordingly, we tested adriamycin for whether the combina-
tion with TRAIL could induce synergistic cell killing in TRAIL-
resistant esophageal cancer cells. When TRAIL was added to
the TRAIL-resistant HCE4, TE3, and TE5 that were pretreated
with adriamycin (0.5 mM) for 16 h, the cells underwent
apoptosis and the effect was synergistic (Figure 2a;
AdriaþTRAIL/no inhibitor). We then checked the effect of z-
LEHD-FMK on synergistic cell killing driven by the combina-
tion between adriamycin and TRAIL because z-LEHD-FMK is
required to protect normal epithelial cells from killing by
TRAIL. In case of HCE4, the cells were still killed in a
synergistic way but in the cases of TE3 and TE5, the presence
of z-LEHD-FMK almost completely blocked cell killing
(Figure 2a; AdriaþTRAIL/C9I). We also checked mitochon-
drial membrane potential (Dcm) change after adriamycin
treatment and we observed a drop of Dcm only in HCE4 cells
(Figure 2b). Bax translocation from the cytosol to the
mitochondria after adriamycin treatment also was observed
only in the HCE4 cells (data not shown). According to these
results, we speculated that the discrepancy might originate
from the mitochondria and possible expression of Bcl-xL.
Therefore, we correlated the expression level of antiapoptotic
Bcl-xL and found a correlation between Bcl-xL expression and
sensitivity to adriamycin (Figure 2b and c). Thus, we tested
another cell line, TE9, that showed low-basal expression of
Bcl-xL and the results were the same as those from HCE4
(data not shown, and Figure 2c). To confirm the effect of Bcl-
xL on the synergistic cell killing, we introduced Morpholino-
modified antisense Bcl-xL oligonucleotides (AS Bcl-xL) into
TE5. Upon introduction of AS Bcl-xL, we observed the
suppression of endogenous Bcl-xL by Western immunostain-
ing (Figure 2d inset), and this correlated with synergistic
apoptotic cell death even in the presence of z-LEHD-FMK
(Figure 2d), similar to what was observed in HCE4 or TE9
(data not shown). On the other hand, EPC2 was also
synergistically killed by the combination of TRAIL and
adriamycin, but it was almost completely protected from cell
killing in the presence of z-LEHD-FMK (Figure 1d). Adriamy-
cin did not induce a drop ofDcm in EPC2 (data not shown) and
the expression level of Bcl-xL is higher than that of HCE4 or
TE9 (Figure 2c). Taken together, these results suggest that
synergistic cell killing by the combination between adriamycin
and TRAIL can be achieved in TRAIL-resistant cancer cells
without inducing apoptosis in normal esophageal epithelial
cells in the presence of z-LEHD-FMK. However, the success
of the combined treatment may depend on the basal
expression level of antiapoptotic Bcl-xL.
We found that normal human esophageal epithelial cells are
susceptible to TRAIL-mediated apoptosis even at low
concentrations (5, 10, 25, or 50 ng/ml) of TRAIL, while human
foreskin keratinocytes are not susceptible at those concentra-
tions. The use of z-LEHD-FMK could completely protect the
esophageal epithelial cells from TRAIL-mediated apoptosis
without affecting cell death in TRAIL-sensitive esophageal
cancer cells. These results using esophagus as a model are
similar to what we previously reported21 with human hepato-
cytes and other tumor types and thus, we believe that a brief
period of caspase 9 inhibition during TRAIL administration
may widen the therapeutic window and allow cancer cell killing
while protecting normal cells. These results also suggest that
different types of normal human tissues may display different
sensitivities to TRAIL. We tested the effect of combining
TRAIL and adriamycin on TRAIL-resistant esophageal cancer
cell lines and on EPC2. Synergistic cell killing was observed
both in TRAIL-resistant cancer cells and in EPC2. Then, we
wondered whether the presence of z-LEHD-FMK could still
protect EPC2 from apoptotic cell killing induced by the
combination. We believe the results are exciting because
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the presence of z-LEHD-FMK could rescue EPC2 almost
completely from cell killing by the combination. We found that
the cancer cells (HCE4 and TE9) that were still killed even in
the presence of z-LEHD-FMK showed a low basal expression
of Bcl-xL, and a drop of Dcm and Bax translocation after
adriamycin treatment was observed only in those cells. The
presence of the caspase 9 inhibitor did not affect the change in
Dcm or bax translocation (data not shown). It has been
suggested that antiapoptotic Bcl-2 family members, such as
Bcl-2, and Bcl-xL, may play central roles in preventing the loss
of Dcm, the release of cytochrome c, and the initiation of
apoptosis,20 and the amount of expression of endogenous
Bcl-xL inversely correlates with apoptotic cell death.
21
Although EPC2 apparently uses a type II pathway in TRAIL-
mediated apoptotic signaling, TRAIL-sensitive esophageal
cancer cells appeared to utilize a type I pathway. The present
studies are beginning to unravel the molecular determinants
as well as patterns of TRAIL sensitivity and resistance in
esophageal squamous cell cancer. Bcl-xL appears to be
overexpressed in human squamous cell esophageal cancers
and could contribute to TRAIL resistance. In cases where Bcl-
xL expression is high and contributes to TRAIL resistance, a
strategy using antisense blockade of Bcl-xL may resensitize
the cells to TRAIL plus chemotherapy.
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Figure 2 Targeting Bcl-xL may result in sensitization of TRAIL-resistant esophageal squamous cell carcinomas to TRAIL, while use of caspase 9 blockade still permits
death of the cancer cells by TRAIL plus adriamycin. (a) Active-caspase 3 assay for apoptosis after the combination of adriamycin and TRAIL treatment of TRAIL-resistant
HCE4, TE3, and TE5 cells. The cells were pretreated with 0.5 mM adriamycin for 16 h followed by incubation for 4 h in the presence of TRAIL. z-LEHD-FMK (20 mM final
concentration) was added (as indicated) at 2 h before the addition of TRAIL. (b) Mitochondrial membrane potential change after adriamycin treatment. To detect a
change in the mitochondrial membrane potential (Dcm) after treating cells with adriamycin, 3, 30-dihexyloxacarbocyanine iodide (DiOC6 (3)) was used. Briefly, 5 105
cells/well were seeded onto a six-well plate. After treatment with adriamycin (0.5 mM final concentration) for 16 h, the cells were harvested, washed and resuspended in
complete media containing 100 nM DiOC6 (3) followed by 30 min of incubation in a 371C water-bath. After incubation, the change of DiOC6 (3) fluorescence was
analyzed by flow cytometry using a Beckman–Coulter Epics Elite analyzer. (c) Basal expression of Bcl-xL in EPC2, HCE4, TE9, TE3, and TE5. To compare the
expression level of Bcl-xL, lysates were subjected to 15% SDS-PAGE. (d) Effect of suppression of endogenous Bcl-xL in TE5. Either the morpholino-modified control
oligonucleotide (Control or C in inset box) or the morpholino-modified antisense Bcl-xL (AS Bcl-xL or AS in inset) oligonucleotides were delivered to the cells by the scrape
delivery method. The active-caspase 3 assay was performed after each treatment (as indicated). Insets show the expression level of Bcl-xL (upper bands) and actin
(lower bands) in TE5 cells after the corresponding oligonucleotide treatment. Morpholino-modified antisense Bcl-xL oligonucleotides (5
0-CGGTTGCTCTGAGA-
CATTTTTATA-30) designed to suppress expression of endogenous Bcl-xL in vivo, and fluorescein-labeled standard control oligonucleotides were purchased from Gene
Tools, LLC (Corvallis, OR, USA). The scrape delivery method was used to deliver the oligonucleotides to the cells. Briefly, cells (1 106/well) were seeded onto a six-well
culture plate and after 16 h of incubation, the medium was changed to 1 ml of fresh medium containing 20 mM Morpholino-modified oligonucleotides. The cells were
scraped out of the plates using a cell scraper (SARSTEDT, Newton, NC, USA). After two gentle up and down pipetting steps, the cells were transferred to a new culture
plate. After 48 h of incubation, the cells were treated with the indicated conditions as described in the figure legends
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